Luca Triggiani
University of Brescia
Quality of lifeCancerInternal medicineRadiologyUrologySurgeryOncologyRetrospective cohort studyGlioblastomaHead and neck cancerChemotherapyAndrogen deprivation therapyMetastasisDiseaseConcomitantProstatectomyProstate cancerPopulationToxicityNuclear medicineIn patientCancer researchRadiation therapyMedicine
Publications 111
#1Stefano Maria Magrini (University of Brescia)H-Index: 25
#2Andrea Emanuele Guerini (University of Brescia)H-Index: 3
Last. Michela Buglione (University of Brescia)H-Index: 21
view all 9 authors...
Background null The impact of coronavirus disease 2019 (COVID-19) has been overwhelming on patients with cancer, who may be at higher risk of developing severe disease. During the second COVID-19 outbreak in Italy, we planned universal microbiologic screening for patients scheduled for antineoplastic treatment. null Methods null All patients with planned active treatment at Brescia University Radiation Oncology Department were screened for severe acute respiratory syndrome coronavirus 2 (SARS-Co...
#1Michela Buglione (University of Brescia)H-Index: 21
#2Andrea Emanuele Guerini (University of Brescia)H-Index: 3
Last. A. AlghisiH-Index: 1
view all 15 authors...
Abstract null null Background null Secondary malignant neoplasms (SMNs) and cardiovascular diseases induced by chemotherapy and radiotherapy represent the main cause of excess mortality for early-stage Hodgkin lymphoma patients, especially when the mediastinum is involved. Conformal radiotherapy techniques such as Intensity-Modulated Radiation Therapy (IMRT) could allow a reduction of the dose to the organs-at-risk (OARs) and therefore limit long-term toxicity. null null null Methods null We per...
#1Rosario MazzolaH-Index: 19
#2Giulio Francolini (UniFI: University of Florence)H-Index: 13
Last. Filippo Alongi (UniFI: University of Florence)H-Index: 1
view all 10 authors...
Abstract Background The present analysis aims to compare the impact of 18F-Choline and 68Ga-PSMA PET-CT guided metastases-directed therapies (MDT) in castration-sensitive oligorecurrent prostate cancer (PC) patients. Material/methods Inclusion criteria were: i) histologically-proven prostate adenocarcinoma, ii) evidence of biochemical relapse after primary tumor treatment, iii) ≤3 hypermetabolic oligorecurrent lesions detected by 18F-Choline or 68Ga-PSMA PET-CT, iv) PET-CT imaging performed in a...
11 CitationsSource
#1Ercole MazzeoH-Index: 4
#1E. MazzeoH-Index: 8
Last. Stefano Maria MagriniH-Index: 25
view all 22 authors...
BACKGROUND AND PURPOSE Two previous "Patterns Of Practice" surveys (POP I and POP II), including more than 4000 patients affected by prostate cancer treated with radical external beam radiotherapy (EBRT) between 1980 and 2003, established a "benchmark" Italian data source for prostate cancer radiotherapy. This report (POP III) updates the previous studies. METHODS Data on clinical management and outcome of 2525 prostate cancer patients treated by EBRT from 2004 to 2011 were collected and compare...
#1Luca TriggianiH-Index: 15
#2Rosario MazzolaH-Index: 19
Last. Stefano Maria MagriniH-Index: 25
view all 21 authors...
The aim of the present study was to explore the potential impact of upfront metastases-directed therapy (MDT) in terms of prolongation of castration-sensitive phase in a series of oligorecurrent castration-sensitive prostate cancer (PC) patients. The present article is a multicenter retrospective study. The population of interest was castrate-sensitive oligorecurrent PC, defined as the presence of 1-3 uptakes in non-visceral sites such as bones or nodes detected by means of 18F-Choline PET/CT or...
1 CitationsSource
#1Mauro Gacci (UniFI: University of Florence)H-Index: 49
#2Walter Artibani (University of Verona)H-Index: 53
view all 371 authors...
Therapeutic strategies for prostate cancer (PCa) have been evolving dramatically worldwide. The current article reports on the evolution of surgical management strategies for PCa in Italy. The data from two independent Italian multicenter projects, the MIRROR-SIU/LUNA (started in 2007, holding data of 890 patients) and the Pros-IT-CNR project (started in 2014, with data of 692 patients), were compared. Differences in patients’ characteristics were evaluated. Multivariable logistic regression mod...
#1Lilia Bardoscia (University of Brescia)H-Index: 6
#2Luca Triggiani (University of Brescia)H-Index: 15
Last. Alessandro Antonelli (University of Brescia)H-Index: 30
view all 14 authors...
PURPOSE To retrospectively review our 20 year experience of multidisciplinary management of non-metastatic ductal prostate cancer (dPC), a rare but aggressive histological subtype of prostate cancer whose optimal therapeutic approach is still controversial. METHODS Histologically confirmed dPC patients undergoing primary, curative treatment [radical prostatectomy (RP), external beam radiotherapy (EBRT), and androgen deprivation therapy (ADT)] were included, and percentage of ductal and acinar pa...
#1Rosario MazzolaH-Index: 19
#2Barbara Alicja Jereczek-Fossa (IEO: European Institute of Oncology)H-Index: 36
Last. Filippo Alongi (University of Brescia)H-Index: 33
view all 14 authors...
In the last years, several evidences demonstrated the role of stereotactic body radiotherapy (SBRT) in the oligometastatic disease and the possibility to increase survival in selected patients. In 2020 the study group "biology and treatment of the oligometastatic disease" of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) conducted a survey evaluating the attitude of physicians in treating the oligometastatic disease and the definition of it. An electronic questionnaire was ...
#1Marianna Noale (National Research Council)H-Index: 24
#1Marianna NoaleH-Index: 20
Last. Stefano Maria MagriniH-Index: 25
view all 15 authors...
Radiotherapy (RT) represents an important therapeutic option for the treatment of localized prostate cancer. The aim of the current study is to examine trajectories in patients’ reported quality of life (QoL) aspects related to bowel function and bother, considering data from the PROState cancer monitoring in ITaly from the National Research Council (Pros-IT CNR) study, analyzed with growth mixture models. Data for patients who underwent RT, either associated or not associated with androgen depr...
#1Carlotta PalumboH-Index: 6
#2Alessandro Antonelli (University of Brescia)H-Index: 30
Last. Alfredo Berruti (University of Brescia)H-Index: 66
view all 13 authors...
BACKGROUND Luteinizing hormone-releasing hormone (LHRH)-agonists in prostate cancer (PCa) patients induce sarcopenic obesity. The effect of LHRH-antagonist on body composition has never been explored. We evaluated changes in fat (FBM) and lean body mass (LBM) in PCa patients undergoing Degarelix. METHODS This is a single-center prospective study, enrolling 29 non-metastatic PCa patients eligible to LHRH-antagonist from 2017 to 2019. All patients received monthly subcutaneous injection of Degarel...
1 CitationsSource